06978 永泰生物－Ｂ
按盘价 
2.500 +0.010 (+0.402%) 盈利能力分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 资产回报率 (%) | -39.553% | -26.506% | -38.803% | -32.179% | -30.696% |
| 股东资金回报率 (%) | N/A | -233.174% | -98.180% | -47.811% | -36.334% |
| 资本运用回报率 (%) | -205.904% | -139.657% | -105.952% | -47.411% | -38.604% |
边际利润分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 毛利率 (%) | N/A | N/A | N/A | N/A | N/A |
| 未计利息、税项、折旧及摊销前利润率 (%) | N/A | N/A | N/A | N/A | N/A |
| 税前边际利润率 (%) | N/A | N/A | N/A | N/A | N/A |
| 纯利率 (%) | N/A | N/A | N/A | N/A | N/A |
变现能力分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 流动比率 (X) | 0.350 X | 0.203 X | 0.403 X | 0.567 X | 2.289 X |
| 速动比率 (X) | 0.350 X | 0.203 X | 0.403 X | 0.567 X | 2.289 X |
财务杠杆分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 总负债 / 总资产比率 (%) | 102.854% | 102.917% | 79.807% | 42.421% | 25.008% |
| 总债项 / 总资产比率 (%) | 17.191% | 68.179% | 54.021% | 17.034% | 10.117% |
| 净债项 / 总资产比率 (%) | 8.159% | 59.854% | 47.858% | 10.388% | -22.072% |
| 总债项 / 股东资金比率 (%) | N/A | N/A | 263.324% | 29.464% | 13.506% |
| 长期债项 / 股东资金比率 (%) | N/A | N/A | 60.856% | 24.339% | 11.048% |
| 净债项 / 股东资金比率 (%) | N/A | N/A | 233.280% | 17.968% | -29.466% |
| 净现金 / (债项) ($) | (4.92千万) | (3.38亿) | (4.05亿) | (9.14千万) | 2.42亿 |
| 每股净现金 / (债项) ($) | (0.080) | (0.603) | (0.787) | (0.178) | 0.471 |
| 总债项 / 资本运用比率 (%) | 92.476% | 287.336% | 144.671% | 22.327% | 12.103% |
| 利息盈利率 (X) | N/A | N/A | N/A | N/A | N/A |
营运效率分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 存货周转率日数 (日) | N/A | N/A | N/A | N/A | N/A |
| 应收贸易帐周转率日数 (日) | N/A | N/A | N/A | N/A | N/A |
| 应付贸易帐周转率日数 (日) | N/A | N/A | N/A | N/A | N/A |
| 备注： | 实时报价更新时间为24/03/2026 17:59 |
| 港股实时基本市场行情由香港交易所提供; 香港交易所指定免费发放实时基本市场行情的网站。 | |
| 股东应占溢利/(亏损) (千) | RMB -230,785 |
| 增长率 | 23.473% |
| 每股盈利/(亏损) | RMB -0.420 |
| 每股账面资产净值 (¥) | RMB -0.023 |